MR imaging of the brachial plexus: Current imaging sequences, normal findings, and findings in a spectrum of focal lesions with MR-pathologic correlation
“…MRI is now regarded as the imaging modality of choice in brachial plexopathy [11][12][13]. While MRI demonstrated structural integrity of the cervical roots and brachial plexus, which corroborated our observations of progressive clinical improvement, electrophysiology was adjunctive in providing evidence for functional aspects.…”
“…MRI is now regarded as the imaging modality of choice in brachial plexopathy [11][12][13]. While MRI demonstrated structural integrity of the cervical roots and brachial plexus, which corroborated our observations of progressive clinical improvement, electrophysiology was adjunctive in providing evidence for functional aspects.…”
“…MRI is currently the preferred modality for brachial plexus assessment . Routine examination protocols typically consist of 2D acquisitions in multiple anatomical planes, 3D imaging, or some combination of both . Recently, Tagliafico et al showed that 2D and 3D sequences generate similar image quality and nerve conspicuity for plexus MRI .…”
Section: Discussionmentioning
confidence: 99%
“…Vargas et al prescribed quiet breathing during data collection to minimize lung motion . Alternatively, Kichari et al employed a combination of breath holding and RT . However, quiet breathing and/or breath holding are not always clinically feasible and are unreliable for motion suppression, as they require adequate patient compliance.…”
Section: Discussionmentioning
confidence: 99%
“…More than two decades ago, Posniak et al mentioned the potential use of respiratory motion compensation for brachial plexus MRI . However, to our knowledge, prospective, respiratory bellows gating is not routinely used in practice …”
Background
Oblique sagittal MRI sequences, orthogonal to the longitudinal axis of the brachial plexus, can reliably depict morphologic and signal abnormalities. However, nerve visualization may be obscured by ghosting artifact from periodic respiratory motion. Respiratory triggering (RT) with a thoracoabdominal bellows can reduce ghosting artifact, but it is not routinely used for brachial plexus MRI. Furthermore, the efficacy of prospective RT for brachial plexus imaging has not yet been reported.
Purpose
To compare brachial plexus MRI sequences acquired with and without respiratory triggering.
Study Type
Prospective.
Subjects
Five volunteers and 20 patients were included. Each subject was imaged with and without RT during the same session.
Field Strength/Sequence
Proton density or T2‐weighted Dixon fat suppressed sequences were obtained at 3.0T using receive‐only 16‐channel flexible array coils.
Assessment
Three musculoskeletal radiologists blindly evaluated each sequence using subjective scoring criteria for ghosting artifact, nerve conspicuity, and diagnostic confidence. Nerve conspicuity scores at three distinct plexus levels were summed to calculate an overall image quality score.
Statistical Tests
Marginal proportional odds logistic regression models were used to compare all scores between RT and non‐RT. Gwet's agreement coefficient was used to assess interobserver and intraobserver reliability.
Results
Mean scan time per sequence increased from 4:25 minutes (95% confidence interval [CI], 4:02–4:49 min) with non‐RT to 6:09 minutes (95% CI, 5:42–6:35 min) with RT. RT reduced ghosting artifact (odds ratio [OR] = 0.21, 95% CI: 0.09–0.46, P < 0.001), improved overall image quality (OR = 4.88, 95% CI: 2.18–10.95, P < 0.001), and increased diagnostic confidence (OR = 3.72, 95% CI: 1.61–8.63, P = 0.002) for all readers. Interobserver agreement for ghosting artifact and image quality was substantial to almost perfect (AC2 = 0.74–0.85). Interobserver agreement for all other scores was moderate to almost perfect (AC2 = 0.61–0.82). Intraobserver agreement was substantial to almost perfect for all parameters (AC2 = 0.76–1.0).
Data Conclusion
Prospective RT with bellows can effectively minimize ghosting artifact and improve image quality for brachial plexus MRI within clinically optimal acquisition times.
Level of Evidence: 1
Technical Efficacy: Stage 2
“…These were apparent on the physical examination in 22 patients, but, like others, we found imaging necessary to detect brachial plexus involvement in M0, no distant metastases other than axillary nodes c N0, no involved axillary nodes; N1, at least one axillary node; N2, matted axillary nodes d M1, metastases to distant sites, such as bone or lung, detectable by imaging e The supraclavicular and axillary regions were included in the radiation portal in 10 of the 13 patients who received primary radiation f Adjuvant or neoadjuvant chemotherapy, or initial chemotherapy for those patients who presented with metastatic disease g Long-term tamoxifen or anastrazole therapy; all these patients previously had chemotherapy h Months elapsing between original breast cancer presentation and fi rst evidence of brachial plexus syndrome a Narcotic analgesics not necessary to control pain b Narcotic analgesics necessary to control pain c Paresis relative to contralateral arm d Severe disability or complete paralysis e C5-6 Division involvement f C7-T1 Division involvement some patients. [11][12][13][14][15][16] In one patient computer-automated tomography, and in 4 magnetic resonance imaging (MRI) was necessary to demonstrate loco-regional metastases, including tumor within the brachial plexus. Two patients without loco-regional metastases developed pain and arm weakness 14 and 32 months after surgery and radiation.…”
The BPS in BC patients is due to loco-regional metastases and is often associated with arm edema. Chemo- or endocrine therapy induced the remission of pain and deficits as frequently as radiation therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.